Testing a new drug for brain tumors that have stopped responding to treatment
Part of Cancer clinical trials.
This trial tests how well different doses of a new drug, BI 764532, are tolerated by people with a specific type of brain tumor (glioma) that has not responded to standard treatments. The drug targets a protein on the tumor cells, which may help slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a certain type of brain tumor (diffuse glioma) that has grown despite standard treatments.
- Your tumor must show a specific protein marker (DLL3) on a tissue sample.
- You have had at least one scan showing your tumor has grown after radiation or chemotherapy.
- You are in generally good health (able to care for yourself, up and about more than 50% of waking hours).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.
This trial tests whether customized drug screening on your tumor cells can help doctors choose the best treatment for you. Your tumor cells will be grown in the lab and tested against different drugs to find what works best, combined with short-course radiation therapy.
This trial tests a new experimental drug (FZ-AD005) for people with a fast-growing brain tumor called high-grade glioma. The drug is designed to target and attack cancer cells that have a specific protein (DLL3) on their surface, which may help stop the tumor from growing.
This trial tests whether testing drugs on your tumor cells in a lab can help find the best treatment for you. It is for people with a specific type of glioblastoma that has not been treated yet.
This trial tests a new drug called BL-B01D1 for people whose glioblastoma has come back after standard treatment. The goal is to see if the drug can help control the tumor.
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.